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Simple Summary: Tetraspanins are a family of molecules abundantly expressed on the surface of
normal or tumor cells. They have been implicated in recruiting or sequestering key molecular regula-
tors of malignancy of a variety of human cancers, including breast and lung cancers, glioblastoma
and leukemia. Yet, how their actions take place remains mysterious due to a lack of traditional
platform for molecular interactions. The current review digs into this mystery by examining findings
from recent studies of multiple tetraspanins, particularly CD151. The molecular basis for differential
impact of tetraspanins on tumor development, progression, and spreading to secondary sites is
highlighted, and the complexity and plasticity of their control over tumor cell activities and interac-
tion with their surroundings is discussed. Finally, an outlook is provided regarding tetraspanins as
candidate biomarkers and targets for the diagnosis and treatment of human cancer.
Abstract: As a family of integral membrane proteins, tetraspanins have been functionally linked to
a wide spectrum of human cancers, ranging from breast, colon, lung, ovarian, prostate, and skin
carcinomas to glioblastoma. CD151 is one such prominent member of the tetraspanin family recently
suggested to mediate tumor development, growth, and progression in oncogenic context- and cell
lineage-dependent manners. In the current review, we summarize recent advances in mechanistic
understanding of the function and signaling of integrin-associated CD151 and other tetraspanins in
multiple cancer types. We also highlight emerging genetic and epigenetic evidence on the intrinsic
links between tetraspanins, the epithelial-mesenchymal transition (EMT), cancer stem cells (CSCs),
and the Wnt/β-catenin pathway, as well as the dynamics of exosome and cellular metabolism.
Finally, we discuss the implications of the highly plastic nature and epigenetic susceptibility of
CD151 expression, function, and signaling for clinical diagnosis and therapeutic intervention for
human cancer.
Keywords: CD151; tetraspanins; breast cancer; Wnt pathway; integrins; cancer stem cells; exosome;
epithelial-mesenchymal transition (EMT)
1. Introduction
Tetraspanins are a family of integral membrane proteins widely expressed in human
tissues and are linked to normal developmental and physiological processes, immunity, and
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pathologies of many human diseases, including cancer [1–7]. Structurally, these 20–50 kDa
molecules are featured by the presence of highly conserved amino acid residues in each
of their extracellular small and large loops, which are connected to four lipid-interacting
transmembrane domains and two short cytoplasmic tails [8–10]. Despite their high struc-
tural similarity, tetraspanins seem to differ both in their functions and signal transduction.
Notably, a single point mutation or deletion of the CD151 or CD37 gene leads to kidney and
skin malfunctions or defective immunity in both humans and mice, while the targeted dele-
tion or alternative splicing of tetraspanin CD9, CD37, CD53, CD81, and CD82 (singularly
or in combination) profoundly impairs function or maturation of B and T lymphocytes
and myeloid lineage cells or tissue metabolism in vertebrates [4,7,11–19]. Aberrant ex-
pression of tetraspanins have been observed in tumor tissues across a wide spectrum of
cancer types, ranging from breast, colon, ovarian and prostate cancers to glioblastoma and
leukemia [1,20,21]. A series of in vitro and in vivo and clinical studies have highlighted
strong roles of these integral membrane proteins in tumor growth, metabolism, angiogen-
esis, and metastatic dissemination [22–27]. Additionally, within the tetraspanin family,
CD151 has long been regarded as a potent driver for cell adhesion and behaviors, and
tumor onset, growth, angiogenesis and metastatic dissemination, and cancer relapse or
resistance to current chemo- and targeted therapies [1,28–32].
Intriguingly, there is growing evidence that many tetraspanins such as CD151 and
CD82 can negatively or positively influence tumor development and metastasis in onco-
genic context- and cell lineage-dependent manners, where they regulate strength of
cell-cell junctions, signal transduction of the Wnt pathway, the epithelial-mesenchymal
transition (EMT), maintenance of cancer stem cells (CSCs), and dynamics of exosomes
(Table 1) [20,21,28,33–35]. This emerging paradigm presents a challenge to conceptualize
functional and signaling roles of the tetraspanin family in human cancer, and their util-
ities as biomarkers and drug targets for cancer diagnosis and treatment. In the current
review, we will summarize this dilemma for tetraspanin molecules, particularly CD151,
and discuss their implications for conceptualizing the role of tetraspanins in human cancer
at the cellular, signaling, and epigenetic levels. In addition, our review will be concentrated
on the evolving role of CD151 and associated protein complexes in breast, ovarian and
prostate cancers, and glioblastoma, as well as their potential for clinical application.
Table 1. A glance of tumor-promoting and suppressing roles of tetraspanin molecules across human epithelia-
origin cancers *.
Genes Pro-Malignant Roles Tumor-Suppressive Roles
CD151
• Promote prostate cancer malignancy by
impacting cancer stem cells and tumor
metastasis [36,37].
• Promote breast cancer cell proliferation and
invasion through regulation of TGF-β1/SMAD
pathway [38].
• Support tumor invasive behaviors via control
of RhoA signaling [39].
• Drive glioblastoma malignancy by supporting
tumor cell migration, CSCs and exosome
release [40–43].
• Promote tumor progression via sustaining
collective cell migration and signaling in skin
carcinoma [44,45].
• Suppress prostate cancer metastasis via regulation of
cell-cell contact and EMT [46,47].
• Suppress inflammatory breast cancer through regulation
of macrophage recruitment [48].
• Suppress tumor cell proliferation and invasion in lobular
breast cancer subtype and ovarian cancer [49,50].
• Trigger anti-tumor immunity in breast cancer [51].
CD9
• Promote tumorigenesis in breast cancer [52].
• Support pancreatic cancer development via
regulation of cancer stem cells and glutamine
metabolism [27].
• Suppress lung cancer metastasis [53].
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Table 1. Cont.
Genes Pro-Malignant Roles Tumor-Suppressive Roles
CD81
• Promote breast cancer metastasis [2].
• Support metastatic progression in breast cancer
and osteosarcoma [54,55].
• Suppress bladder cancer cell invasion [56].
CD82
• Promote EMT in liver cancer and metastatic
potential of malignant prostate carcinoma PC-3
cell line [35,57].
• Suppress tumor cell migration and invasion [58].
• Suppress melanoma motility by interfering CD44
splicing [59].
• Suppress EMT in prostate cancer [34].
• Repress tumor cell motility through control of
extracellular vesicle production and architecture of
plasma membrane [60].
TSPAN12
• Promote breast cancer metastasis through the
Wnt/β-catenin pathway [61].
• Drive impact of tumor-associated fibroblasts on
tumor cell invasion [62].
• Suppress tumor progression in non-small cell lung
cancer (NSCLC) [63].
TSPAN8
• Support cancer stem cells via Sonic Hedgehog
pathway [64,65].
• Promote tumor cell invasion and metastasis
[25,30,66].
• Suppress NSCLC metastasis by affecting activity of
extracellular vesicles [67].
*: A small fraction of studies listed are on melanoma or glioblastoma. CSC, cancer stem cell; EMT, epithelial-mesenchymal transition.
2. The Complex Role of CD151 in Tumor Metastasis
2.1. Early Studies and Present Views on the Pro-Metastatic Role of CD151
The link between CD151 and human cancer was initially implicated following dis-
covery of its co-translation with laminin-binding α3β1 integrin in human carcinoma cells
or modulation of αIIbβ3 function in platelets [6,22,68,69]. The hard evidence of a role of
CD151 in cancer, however, came from detection of elevated CD151 expression in metastatic
tumor cells and the inhibition of cell motility by an anti-CD151 monoclonal antibody [5].
This pro-metastatic role was subsequently confirmed by a large body of cell line-based
in vitro studies in multiple cancer types and has been substantiated by its pro-invasive and
pro-angiogenic functions [1,70,71]. More recently, we and others have detected a marked
decrease in the formation of pulmonary metastases in breast cancer upon CD151 deletion
or knockdown in MMTV-ErbB2 or MMTV-PyMT transgenic or xenograft model [28,32,38].
In line with this evidence, CD151 expression appears elevated at the mRNA level in
metastatic tumors and is associated with poor clinical outcomes in the ErbB2+ breast cancer
subtype [32]. Collectively, these in vitro and in vivo investigations, along with clinical
analyses, underpin CD151 as a premier player in human cancer metastasis.
Mechanistically, downregulation or removal of CD151 markedly impairs integrin-
dependent tumor cell adhesion, motility, and invasion [21,72]. Studies from our groups
and others have also implicated that the pro-metastatic function of CD151 is in part
tied to its impact on tumor cell survival or their resistance to anoikis [21,32,71]. Pres-
ence of CD151 molecules in tumor cells appears to facilitate the clustering/activation of
laminin-binding (LB) integrins (α3β1, α6β1 and α6β4) on the cell surface, which in turn ac-
tivates SFKs/FAK-, JAK/STAT3-, RAS/MEK- and NF-kB-dependent signaling pathways,
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cytoskeleton remodeling, and diverse cellular activities and behaviors [32,38,44,71,73].
Interestingly, in breast cancer cells exhibiting a strong promoting role of CD151, receptor ty-
rosine kinases (RTKs) (e.g., EGFR, ErbB2, c-Met and Ron) or K-Ras are frequently activated
because of gene amplification/overexpression or mutations (Figure 1) [1].
Figure 1. The pro-metastatic function and signaling pathways driven by CD151/laminin-binding
(LB) integrin complexes and their crosstalk with oncogenic receptor tyrosine kinases (RTKs) in cancer
cells and endothelial cells. The role of CD151 illustrated in a gain-of-function manner is based on
observations from a series of studies with gene-targeted or shRNA knockdown effect in mouse
models or cancer cell lines.
Part of the pro-metastatic role of CD151 may be linked to its regulation of tumor angio-
genesis and microenvironments, as it supports function and integrity of vascular endothe-
lial cells and infiltration of tumor-associated macrophages [25,28,48,74,75]. Consistent with
these observations, CD151 deletion markedly decreases expression of several key myeloid
cell-associated hallmark genes in mammary tumors, including CD36 and MMP2 [28]. Such
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notion is also supported by recent findings on the role of CD151-associated α6β4 integrin
in macrophages [76]. Additionally, CD151 is implicated to propel tumor progression by
regulating integrity and trafficking of exosomes produced in tumor-associated fibroblasts
and the Wnt pathway [30,77,78]. In some cancer types, the pro-metastatic role of CD151
appears to be achieved through strong synergy with other tetraspanins (e.g., TSPAN8) [25].
Hence, the impact of CD151 on cancer metastasis largely stems from regulation of tumor
cell behaviors and survival, and their microenvironments.
2.2. Emerging Evidence of an Anti-Metastatic Role
Unexpectedly, several recent studies have implicated CD151 as a suppressor of tu-
mor metastasis, particularly in ovarian and prostate cancers [46,47,49,79]. A parallel
scenario has also been raised for other tetraspanins, such as CD9 and CD82, traditionally
regarded as bona fide metastasis suppressors (Table 1). This is a sharp deviation from
the well-established paradigm of CD151 being pro-metastatic and CD9/CD82 being anti-
metastatic [1]. In fact, the current view of the pro-metastatic role of CD151 in prostate
cancer was largely drawn from studies with the endocrine subtype-related Tramp model,
and analyses with the PC-3 cell line which is regarded as oncogene-targeting squamous
epithelial cells [35,36,46,80]. In contrast, the studies suggesting an anti-metastatic role of
CD151 were performed with the oncogene-targeting cells falling into the differentiated ep-
ithelial cell category, where CD151 is abundantly expressed at the cell-cell junction [46,47].
In such context, loss of CD151 at cell-cell junctions leads to induction of EMT or a highly
motile/invasive mesenchymal cellular phenotype featuring altered expression of typical
epithelial (e.g., E-cadherin) and mesenchymal makers (e.g., vimentin, fibronectin and tran-
scription factors Slug/Snail, etc.), enhanced tumor cell motility and invasiveness, as well as
strong extracellular matrix (ECM)- arginine-glycine-aspartate (RGD) motif-binding integrin
interactions [31,81]. Consistent with this line of observations, data from histological and
genomic analyses show that a fraction of human breast and prostate carcinomas may arise
from PTEN or E-cadherin mutations or loss in differentiated epithelial cells [46]. It may
also be linked to activation of the non-canonical Wnt pathway [28,46,49]. Furthermore, this
paradigm may be originated from the cell lineage- and the oncogenic context-dependent
role of CD151, highly reminiscent of its associated laminin-binding integrin α3β1 or α6β4
integrin, which seem to vary with cancer subtype or oncogenic context (inactivation/loss
of tumor suppressors p53 and SMAD4 versus activation of Ras oncogene) [82,83]. More
surprisingly, an opposing scenario appears to occur in a group of tetraspanins traditionally
regarded as metastasis suppressors, including CD9 and CD82, in which they seem to
dampen or sequester activation or signal transduction of another class of growth factors or
receptors, such as the membrane-bound TGF-α or TGF-β Type II receptor [84,85].
3. A Oncogenic Context- and Cell Lineage-Dependent Role of CD151 in Tumor
Growth and Metabolism
Aside from being a key player in tumor metastasis, CD151 has long been regarded as
being pro-tumorigenic in multiple cancer types, particularly in breast and skin
cancers [28,29,32,86]. Again, this unidirectional view has recently been challenged by
data from a series of in vivo studies with CD151 gene-targeted mice, transgenic animal
models, and clinical analyses [32,39,71,86]. Because of the strong clinical implications, here
we will discuss this twist by centering around recent studies of CD151 function in solid
tumors, particularly breast and prostate carcinomas.
3.1. Being Pro-Tumorigenic
As one of the most common cancer types among women worldwide, breast cancer
is a highly heterogeneous disease. Based on histological and genetic alterations, breast
cancer is grossly categorized into four major subtypes: estrogen receptor (ER)-negative,
including ErbB2+ and triple-negative, and ER-positive (Luminal A and Luminal B) [87].
The malignancy of these breast tumors is largely driven by activation of the PI3K/Akt
and RAS/MEK/ERK pathways and loss of key tumor suppressors (p53, BRCA1/2, PTEN,
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RB, etc.) [87–90]. In the case of CD151, a series of in vitro and in vivo studies reveal a
strong inhibitory effect of CD151 downregulation or deletion on tumor onset and growth
in either ErbB2+ or basal-like subtypes [29,32,38,71,86]. Collectively speaking, there is
robust evidence that CD151 is pro-tumorigenic in the context of signaling driven by
overexpression/amplification of RTKs or by the oncogenic activation of their downstream
effector pathways (e.g., RAS/ERK1/2 and PI3K/AKT, as well as TGF-β- or Wnt/β-catenin-
mediated pathways) (Figures 1 and 2A).
Figure 2. Emerging evidence on the context-dependent crosstalk between tetraspanin CD151 and
the Wnt signaling pathway in breast cancer. (A) Hypothetical molecular basis for the cooperative
role of CD151/laminin-binding integrin complexes and the Wnt/ pathway in basal cell-origin breast
cancer. (B) A working model for CD151-mediated suppression of the Wnt/β-catenin signaling, and
associated changes in transcription factors Snail and Slug, cell-cell adhesion and EMT in luminal
epithelial cell-origin breast cancer.
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Another developing theme on CD151 in breast cancer is its promoting role in de-
velopment and growth of basal-like mammary tumors driven by the oncogenic Wnt1
pathway [28]. As a key downstream effector of the canonical Wnt pathway, transcrip-
tion factor Myc has long been implicated in regulation of the pro-tumorigenic role of
CD151 in gliomas [43]. Consistent with this notion, we and others have observed a strong
tumor-promoting role of CD151 in glioblastoma [40,42]. Intriguingly, Myc, a key effector
downstream of an array of oncogenic pathways, including RAS/Erk and PI3/Akt /mTOR,
also serves as a master driver of cell metabolism in diverse cancer types, particularly
for nutrients glutamine and glucose [43,90–92]. Following this link, we speculate that
CD151 might promote tumor growth in breast cancer largely through regulation of c-Myc-
driven cellular metabolism. So far, this notion is supported by recent studies of the role
of tetraspanins CD9 and CD81 in metabolism of glutamate and lipids in normal or tumor
tissues [8,11,27].
Importantly, CD151 appears to be a key player in maintenance of tumor-initiating
cells in breast, prostate, and pancreatic cancers, that is, CSCs, as CD151-null/deficient ER+
tumor cells seem unable to sustain the population under in vitro culture [28,37,65,93]. This
line of observation is consistent with the critical role of CD151-associated α6 integrin in
human cancer stem cells across a wide range of human cancer types, particularly breast
cancer and glioblastoma [94,95]. They are also of clinical importance, as CSCs are regarded
as front runners for candidate therapeutic targets given their crucial roles in drug resistance
and disease recurrence in human cancers [96,97].
3.2. Being Tumor-Suppressive
In contrast to the role in ER− breast cancer (basal-like and ErbB2+) summarized above,
CD151 appears to be tumor suppressive in some cases, for example, during the develop-
ment and growth of ER+ mammary tumors in the mouse mammary tumor virus (MMTV)
promoter-driven Wnt1 oncogene model (Figure 2B) [28]. In fact, this unexpected observa-
tion is consistent with our prior analysis of the impact of CD151 deletion on mammary
luminal progenitor cells (CD24high CD49flow population), where CD151 seems involved in
maintenance of quiescence of mammary progenitor cells and the associated impact on mam-
mary gland development [93]. Additionally, it is supported by analyses of CD151 and α3β1
integrin expression in tumor biopsies of lobular or inflammatory breast cancer or colon
and ovarian cancer patients [33,49,50,93]. More surprisingly, removing one or two CD151
alleles seems to have nearly an equivalent effect on tumor growth [28], thus illuminating
the haploinsufficient nature of CD151 gene and a strong player in human cancer.
Furthermore, the unique aspect of the tumor-suppressive role of CD151 is its intrinsic
association with the dynamics of the EMT phenotype, a hallmark trait for the progression
of epithelial-origin tumors [32,49]. It has long been advocated that CD151 is a crucial
contributor of cell-cell adhesion in immortalized epithelial or carcinoma cells [98,99]. In
line with this notion, downregulation or loss of CD151 expression not only weakens such
junctional structures, but leads to activation of the transcription factors Snail and Slug and
associated EMT-like phenotype (Figure 2B) [28,49]. In line with this functional impact, the
downregulation or deletion of CD151 in normal luminal progenitor cells or related breast
cancer cell lines or mammary gland is accompanied by the upregulation of fibronectin
expression and Slug [93]. While this function has been linked to activation of protein kinase
C (PKC) and Cdc42, it remains controversial in terms of integrin involvement [46,47].
One of the noticeable observations from our study with the MMTV-Wnt model was
the absence of tumor-initiating cells in CD151-deficient ER+ mammary tumors [28]. This
phenomenon is highly unexpected, since the canonical Wnt pathway or transcription
factors Snail and Slug or associated EMT have long been regarded as major drivers of the
metastatic progression of ER+ breast tumors [94,100,101]. This may also represent another
layer of complexity of CD151 action in human ER+ breast cancer.
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4. Molecular Basis for Functional and Signaling Versatility of CD151 and
Other Tetraspanins
Mechanistically, the complex role of CD151 in human cancer is intimately linked to
diversity of its laterally associated molecular partners on the cell surface, besides hetero-
geneity in its subcellular localization in tumor cells. Despite lack of extracellular ligands
or classical domains/motifs for intracellular protein-protein interactions, tetraspanins are
capable of carrying out a variety of functional and signaling roles through at least three dis-
tinct types of molecular interactions: (1) Imposing a lateral impact on the activation of their
cell surface partners; (2) Recruiting signaling molecules via self-association-based micro- or
nano-domains; (3) Long-range impact via regulation of secretory vesicles [73,102–105]. To
date, there is a consensus that tetraspanin molecules, together with their molecular partners,
form a nano-scale protein complex or molecular network on the plasma membrane, termed
as tetraspanin-enriched microdomain (TEM) [3,8,10,102,106].
In CD151-based TEM, there exists at least two distinct pools of tetraspanin molecules
on the cell surface. One pool contains large-sized transmembrane protein or receptors
through protein-protein interactions, such as LB-integrins interacting with CD151 through
their extracellular domains [10]. Another pool, based on our prior biochemical and
antibody-based analyses, consists of self-associated or interspecies aggregates of CD151
and other tetraspanins, where they seem localized at the periphery of TEM [103,105,107].
The targeting and stability of this pool of molecules is highly dependent on the palmitoyla-
tion of its membrane-proximal cysteine residues and N-terminal cytoplasmic tail [103,104].
Interestingly, the integrin-absent pool of molecular aggregates of CD151, which presumably
corresponds to the so-called integrin-free CD151 fraction, seems to have a regulatory role
in cell-cell contact and tumor resistance to therapeutic agents [47,108]. More recently, we
and others have noted that some of these molecular interactions varies with cell lineage,
that is the cell-of-origin or differentiation state of oncogene-targeting cells, as well as onco-
genic context (RAS vs. mutation or PTEN mutation) [28,47,49]. Here, we will examine
such advances in the context of both pro- and anti-tumorigenic roles of tetraspanins in
human cancers.
4.1. Hijacking Function and Signaling of Single Transmembrane-Containing Receptor or
Protein Partner
Although many tetraspanins are regarded as key mediators of tumor development
and progression, their actions have been connected to at least two classes of cell surface
molecules: CD151-associated heterodimeric adhesion receptors for laminins, α3β1, α6β1,
and α6β4 integrins, and the CD9/CD81/CD82-binding Ig-G-containing proteins such
as EWI-2 and EWI-F. In the case of CD151, its pro-tumorigenic role is largely carried out
through regulation of function and signaling of laminin-binding integrins (Figure 2A) [32,71].
Studies from our group and others indicate that the pro-metastatic role of CD151 in hu-
man basal-like and ErbB2 breast cancer subtypes is achieved largely through regulating
α6 integrin-dependent cell motility, invasion and survival [45,50]. In particular, CD151
contributes to the lateral clustering in cis of α6 integrins through direct extracellular domain
linkages, which in turn enhances clustering/activation of these adhesion receptors and
subsequent changes in cell-ECM adhesion, cytoskeleton remodeling, and signal transduc-
tion [71,73,109].
The tumor-promoting role of CD151 may also be carried out through regulation of
α3β1 integrin-dependent cell-ECM adhesion, migration, survival, and signaling [50,110–112].
Such impact, however, seems largely restricted to tumor cells with basal cell lineage or a mes-
enchymal phenotype [28,71,113]. In contrast, in tumor cells with strong epithelial cell charac-
teristics, CD151, like α3β1 integrin, is more engaged in the maintenance of cell-cell contact
through basolateral distribution, conferring an anti-tumor role in an integrin-dependent man-
ner or through interacting non-integrin partners or self-association/clustering [47,49,114]. In
this case, CD151 seems to repress tumor cell growth by counteracting EMT in multiple cancer
types, including breast, ovarian and prostate [28,46,49,115]. In fact, this scenario highly
resembles the well-established established tumor-suppressive role of tetraspanins CD82,
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CD9, and TSPAN8 in epithelial-origin cancers, whereby they regulate E-cadherin/β-catenin
complex-dependent cell-cell adhesion [45,50,99,116–118]. For CD9 and CD82, this function
appears to take place through EWI proteins [10,20,21,58]. Interestingly, these tetraspanins
are capable of suppressing metastasis of mesenchymal cell-origin melanoma by sequestering
activation of TGF-β type II receptor [85]. Hence, tetraspanins impact tumor growth and
progression largely through regulation of function and signaling of their major partners in a
parasitic manner, regardless of being pro- or anti-tumorigenic.
4.2. Recruiting Signaling Molecules via the Tetraspanin Self-Associated Membrane Microdomain
Another important mode for tetraspanin-mediated tumorigenesis is to relay PKC-
dependent signaling through formation of tetraspanin-enriched microdomain (TEM) [3,8,10].
Based on biochemical and microscopy-based studies, this type of interaction may in-
volve palmitoylation of multiple membrane-proximal cysteine residues in both N- and
C-terminals of tetraspanin molecules, which provide key support for clustering or oligomer-
ization of these molecules on the cell surface (Figure 2) [102,119,120]. Evidence from exten-
sive biochemical and microscopy studies have firmly established that the primary function
of TEM is to recruit PKC to TEM-associated protein complexes, molecular aggregates or
cluster-like structures on the cell surface [98,120]. In case of CD151, TEM recruits PKC-α to
phosphorylate laminin-binding (LB) α3, α6 or β4 integrins, while CD53-mediated TEM
drives recruitment of PKC-β to BCR complexes in B cells, which in turn leads to signal
transduction [71,73,109]. In this context, the tumor-suppressive role of integrin-free CD151
in prostate cancer [47] may be regarded as recruiting the PKC-like signaling molecules to
strengthen cell-cell adhesion through oligomerized CD151 molecules. Consistent with this
notion, compared to immortalized mammary basal epithelial cells (MCF-10A), luminal
epithelia cells (MCF-7) exhibit relatively poor expression of laminins and LB integrins,
while having strong E-cadherin expression and cell-cell interactions [71,103]. A similar
scenario can be said for the so-called integrin-free CD151 in prostate cancer cells [47].
Moreover, the TEM assembly may involve multiple intracellular membrane compartments,
such as endoplasmic reticulum, Golgi, lysosomal, endosomal and multivesicular bodies,
which have been extensively described by multiple reviews [10,20,21].
Another remarkable advance in our understanding of TEM is that it can be visual-
ized as nanometer-sized molecular aggregates on the cell surface using high-resolution
microscopy [102,119]. These imaging-based findings are consistent with the observation
of molecular composition of TEM from our prior biochemical analyses [71,103,104,114].
This type of approach is of particular value to delineate key molecular components or
interactions in TEM across various cancer types, ultimately accelerating our mechanis-
tic understanding of the crucial role of CD151 and other tetraspanins in tumorigenesis
and metastasis.
4.3. The Long-Range Effect via Regulation of Exosome Formation, Trafficking and Function
Besides TEM, tetraspanins are capable of impacting tumorigenic and metastatic pro-
cesses through regulation of secretory vesicles named as exosomes [30,121,122]. As a class
of extracellular vesicles, exosomes are <200 nm in diameter and formed by cells through
invagination of endosomal and plasma membranes. Exosomes are highly enriched in
tetraspanins, particularly CD63 and CD151, in addition to diverse intracellular components,
including diverse RNA species, metabolites, and proteases [10,121,123]. Given the nature
and signaling capabilities of TEMs, it is of no surprise that many tetraspanins are regarded
as key contributors to a variety of exosome-associated functional roles, ranging from tumor
cell migration, angiogenesis and signal transduction to expression of critical cancer genes
and tumor metabolism through control of micro-RNA or non-coding RNA or metabolite
pools [67,124,125]. In case of CD151, it is suggested to act in concert with TSPAN8 to
drive exosome production in both tumor and endothelial cells, thereby facilitating tumor
metastasis [30,118]. However, the mechanism for tetraspanin-dependent regulation of
exosomes could be far more complex than originally thought, as some tetraspanins seem
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to negatively regulate activity and integrity of key exosome-producing machinery, that
is, the endosomal sorting complexes required for transport (ESCRT) [126]. With variation
in extent of palmitoylation and glycosylation between tetraspanins, they may mediate
exosome functions by modulation of their lipid composition [41]. Finally, Wnt signaling has
long been known for having a long-range effect on tumor immune microenvironments [77].
Given the strong link between CD151 and exosomes, we speculate that the significant role
of CD151 in Wnt-induced mammary tumorigenesis may be partially achieved through
regulation of exosome-mediated delivery of Wnt ligands [28].
Overall, compared to traditional cell surface molecules or receptors, the impact of
CD151 and other tetraspanins on tumor growth and metastasis is more closely linked to
regulation of multi-component protein complexes on the cell surface, extracellular vesicles
and tumor microenvironments.
4.4. Decoding the Myth of the Crosstalk Between Tetrspanins and the Wnt Pathway in
Cancer Cells
Our recent in vivo study suggests additional complexity of tetraspanin function in
cancer cells, particularly in the context of oncogenic activation of the Wnt-dependent
pathway (Figure 2). As one of the widely activated oncogenic pathways, Wnt signaling
involves interactions between extracellular ligands (Wnts) and multi-component protein
complexes on the cell surface composed of seven transmembrane-spanning Frizzled 1-7
and Type I transmembrane co-receptors (e.g., LRP5/6) [127]. Importantly, many of these
components, along with their downstream effectors (i.e., Axin, DVL, β-catenin, and TCF7-
L2) or mediators (e.g., RNF43) are frequently overexpressed or downregulated in human
cancers, particularly those of epithelial cell origin [128–130]. The Wnt pathway can also be
constitutively activated through genetic mutations or deletions of their protein destruction
complexes such as by APC mutation, accompanied by translocation and elevated tran-
scriptional activity of β-catenin [131]. Additionally, the Wnt pathway has been strongly
implicated in tumor recurrence and progression in multiple cancer types [127,132–134].
Our recent study shows that upon CD151 deletion, there was more than 10-fold
increase in the level of nuclear β-catenin as well as the strong cytosolic presence of E-
cadherin in mammary tumors [117]. These molecular and signaling changes ultimately
bolster transcriptional activation of pro-proliferative genes and tumor growth [135,136].
Also, the genes that regulate cell proliferation, survival, and metabolism (e.g., Cyclin D1
and Myb) are strongly affected [127]. Additionally, expression of the genes involved
in regulation of the stability of E-cadherin/β-catenin complexes appeared suppressed,
strengthening the intrinsic role of CD151 in cell-cell adhesion [34,116,117,137]. In contrast,
CD151 disruption markedly blunts survival of epithelial basal cell-derived tumor cells [28],
consistent with the impact of CD151 knockdown on MDA-MB-231 cells [38,71]. Importantly,
these emerging observations on CD151 are in line with the current paradigm over the
crosstalk between other tetraspanins, including TSPAN8, TSPAN5, and CD82, and the
Wnt/β-catenin pathway [1,71,109,138]. Meanwhile, expression of α3 integrin in luminal
cells appear unaffected, implicating that the tumor-suppressive role of CD151 in breast,
prostate and ovarian cancers are attributed to the combined action of integrin- and self-
associated CD151 molecules. As a result, our studies argue that CD151 is a suppressor of
ER+ breast cancer and prostate cancer, as they frequently arise from oncogenic targeting of
luminal or well-differentiated epithelial cells, rather than basal epithelial or progenitor cells.
5. Control of Expression of CD151 and Other Tetraspanins at Multiple Levels
There is evidence that in contrast to traditional oncogenes or tumor suppressors, the
role of tetraspanins including CD151 during carcinogenesis and metastasis is achieved
largely through altered expression level and associated impact on activation state and
signaling strength of their associated receptors or protein complexes in tumor cells. Notably,
very few tetraspanins exhibit functional loss/gain due to genetic alterations (mutations,
amplifications, or deletions) [1,20,54,60]. In this sense, the impact of tetraspanins on cancer
development and progression may primarily stem from their deregulated expression,
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subcellular distribution, and molecular partners. However, there is accumulating evidence
that expression of tetraspanins seems more regulated at transcriptional and epigenetic
levels, largely reminiscent of deregulation of classical tumor suppressors, such as PTEN or
BRCA1/2 genes [89].
Thus far, DNA hypermethylation in cancer cells has been documented for at least
6 members of the tetraspanin family, including CD9, CD81, CD82, CD151, TSPAN1, TSPAN3,
and Uroplakin [46,63,139–143]. Largely occurring in their promoter regions [139,142],
DNA hypermethylation ultimately leads to decreased mRNA and/or protein levels of
tetraspanins in tumor cells or tissues [10,144–147]. Interestingly, this type of regulation ap-
pears common in prostate, colon, and ovarian carcinomas, as well as in neuroblastomas and
glioblastomas [148,149]. The precise mediators behind DNA methylation of tetraspanin
genes however, remain to be identified. Based on recent studies, this type of regulation
may be particularly evident in cancer driven by MYC-N amplification and activation of
inflammation-oriented NF-κB-driven pro-survival network [92], as well as activation of
RTK- or TGF-β receptor-mediated oncogenic pathways [71,85,86,150,151].
The deregulated expression of tetraspanins during tumorigenesis and metastasis may
also be attributed to dynamics of their associated protein partners at the co-translational
level [82,83,152]. In the case of CD151, its downregulation in tumor cells may be associated
with decreased protein expression of α3β1 and α6β4 integrins [32]. There may be a similar
scenario for the decreased expression of CD9/CD81-associated EWI proteins in aggressive
melanoma [85,140,142,153]. Additionally, there is evidence that tetraspanin expression
is regulated through proteasome- or microRNA-mediated biochemical processes [1,151].
Combined, the functional plasticity of tetraspanins during tumorigenesis and metastasis is,
at least in part, achieved by tight regulation of their expression at epigenetic, transcriptional,
and translational levels, and through protein degradation machinery [154].
6. Clinical Significance of Deregulation of CD151 and Its Associated Network
Even though CD151 has a complex role in human carcinomas, the tight link between
CD151 expression and tumor relapse provide a unique window for pursuing CD151 as
a drug target [1,31]. This link is also strongly supported by its role in the differentiation
of mammary progenitor cells (maintenance of quiescence) in CD151-targeted mice and
the MMTV-Wnt model [155,156]. Additionally, CD151 and CD9 are tightly associated
with activities of tumor-initiating cells or CSCs [27,28,37]. Moreover, this potential tar-
geting is bolstered by the wide recognition of the role of CD151-associated α6 integrin in
survival or activity of CSCs and may be attributed to the intimate crosstalk between CD151-
α6 integrin complexes and the RAS/MEK/ERK pathway in basal epithelia cells [28,82].
In this regard, our observed effect of CD151 deletion is consistent with the role of α6
integrin/CD49f-based CSCs in the MMTV-Wnt1 model described by the Perou group [96].
Because CD151 is associated with recurrence of basal-like breast cancer [31], it will be of
interest to determine whether the CSC-associated role of CD151 is recapitulated by use of
more clinically relevant PDX model of breast cancer under taxane-based regimens known
to foster CSCs [157]. This notion is also supported by the evidence that altered CD151
promotes cancer cell resistance to targeted (anti-ErbB receptors) and chemo- therapies
in multiple cancer types [32,40,86,108]. Meanwhile, a number of tetraspanins have been
shown to be key players in hematopoietic stem/progenitor cells [15,93,158]. Conversely,
the strong role of tetraspanins, such as CD151 and CD37, in cell differentiation could serve
as a basis for development of lineage-based targeting, in a manner similar to the antibody
targeting of CD20 [159]. In case of CD37, because of its restricted expression and strong
biological role in mature B lymphocytes, it has been clinically targeted with monoclonal
antibody for leukemia treatment. The efficacy of this approach, however, appears chal-
lenged by emerging incidence of mutations at the critical domain or deletion of this gene
in biopsies in some patient populations [16].
Meanwhile, the prevalence of DNA methylation in the promoter regions of tetraspanins
provides a unique opportunity for the evaluation of tumor progression, as their regulation
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frequently correlates with the onset of metastases in multiple cancer types. Such data
may also provide complimentary support for carcinogenesis in the context of tetraspanin-
enriched exosomes in patient body fluids [54]. Tetraspanins are highly regarded as potential
therapeutic targets, as they support activities and signaling of cancer cells during angio-
genesis and dissimilation to secondary sites of primary tumors [1]. In fact, a number of
function-blocking monoclonal antibodies against tetraspanins are under investigation for
their anti-tumor efficacy [5]. Also, some tetraspanins have been chosen for launching the
chimeric antigen receptor T cell (CAR-T)-based anti-cancer therapy [160]. Meanwhile, the
impact of tetraspanins on EMT, CSCs and other malignant processes is susceptible to the
epigenetic regulation [34,45,49,98,99,117,118,137,161–163]. Thus, targeting DNA hyper-
methylation through chemical inhibitors of DNA methyltransferases, such as 5-Aza-CdR
or HDAC inhibition via Trichostatin A, may provide a means to restore expression of
many tetraspanins and their anti-tumor functions in various carcinomas, such as CD82 and
CD151 in prostate cancer and CD81 in neuroblastomas or glioblastomas [148,149,163–165].
7. Conclusions
The role of CD151 and other tetraspanins during tumor growth and progression has
long been postulated to be manifested through regulation of tumor cell adhesion, survival,
migration, and invasion in an integrin-dependent manner. Especially for CD151, it is
regarded as a key adaptor for activation and signal transduction of multiple LB-binding
integrins on the cell surface [32,39,45,50,71]. Over the past decade, CD151 is increasingly
appreciated as a functionally versatile molecule and driver of human epithelial-origin
cancers whereby it regulates cell-cell junctions, proliferation, EMT, metabolism and CSCs,
as well as tumor microenvironments [54]. These diverse functions highlight a key basis for
the crucial role of CD151 across a wide spectrum of human cancer [1,3]. Additionally, the
presence of CD151 in exosomes derived from tumors or their microenvironments suggests
a new mechanism for its role in tumor relapse and drug resistance [41,48,54]. There is
also evidence on the cell lineage- and oncogenic context-dependent roles of CD151 and
other tetraspanins [28,29,48,50,71,93,166]. However, the underlying genetic, epigenetic and
metabolic mechanisms remain to be defined. With emerging powerful genomic, proteomic,
and metabolomic tools, we will be able to delineate the versatile role of CD151 and other
tetraspanins across different stages of cancer development and progression, progression,
as well as launch a new line of biomarkers and drug targets for the clinical management of
this aggressive disease.
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